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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of taxation of fat content in food on consumption of total fat and saturated fat, energy intake, overweight, obesity,
and other adverse health outcomes in the general population.
B A C K G R O U N D
Description of the condition
Overweight and obesity, i.e. a body mass index (BMI) ≥ 25 and a
BMI ≥ 30, respectively, are increasing worldwide and considered
to be a major public health challenge of the 21st century (WHO
2014; NCD-RisC 2016). The Global Burden of Disease study
estimated that the prevalence of obesity more than doubled be-
tween 1980 and 2013 (Ng 2014). In 2013, approximately 38%
of all adults had a BMI of more than 25; that is, about 2 billion
people, of whom about a third were considered obese. Similarly,
approximately 24% of all children worldwide were estimated to
be overweight or obese. Although the increase of adult obesity has
stabilised (albeit at very high levels) in some high-income coun-
tries (HICs), the prevalence of obesity in low- and middle-income
countries (LMICs) and several HICs is continuing to rise (Ng
2014; Seidell 2015). The reasons for these trends are complex and
influenced by a broad variety of social determinants of health, such
as urbanisation, changes in types of employment, and alterations
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to the food supply (Lang 2009). In LMICs the rise has been partly
attributed to economic modernisation and lifestyle changes, i.e.
a nutrition transition to a ’Western diet’ that is broadly defined
by high intake of refined carbohydrates, added sugars, fats, and
animal-source foods (Goryakin 2015; Popkin 2012).
Obesity is a major risk factor for mortality and morbidity
(Lhachimi 2013). In 2010, overweight and obesity were estimated
to cause 3.4 million deaths, contributed 3.9% of years of life lost,
and 3.8% to the global burden of disease (measured in disability-
adjusted life years) (Ng 2014). In particular non-communicable
diseases (NCDs), such as type 2 diabetes, cardiovascular diseases
(CVDs), certain cancers, and musculoskeletal disorders, are po-
tential health consequences of a raised BMI (Guh 2009). This also
makes obesity a significant factor for disability (Lhachimi 2016).
NCDs are already the leading cause of death in HICs and are on
the rise in LMICs (WHO 2014). Moreover, the increased preva-
lence of chronic diseases in regions where individuals have insuf-
ficient access to appropriate health care may exacerbate the harm-
ful consequences of obesity on morbidity and mortality for those
populations. For example, if an obese person with type 2 diabetes
does not have regular access to insulin, this may result in particu-
larly premature death, disability, or morbidity (Seidell 2015).
Overweight and obesity are often defined as the “abnormal or ex-
cessive body fat accumulation in adipose tissue” (WHO 2000;
WHO 2011). At the individual level, overweight and obesity are
mainly caused by an imbalance in energy intake and energy expen-
diture. The member states of the Food and Agriculture Organiza-
tion (FAO) and the World Health Organization (WHO) in their
2014 Declaration of Rome on Nutrition noted certain aspects of a
diet that increase the susceptibly to both overweight and obesity, as
well as comorbid NCDs; chief among them consumption of food
that is high in fat (FAO/WHO 2015). Fats are energy dense (i.e.
37 kJ or 9 kcal per gram), a contributor to the palatability of food,
and enable absorption of fat-soluble vitamins. Moreover, fats are
crucial for development and survival during the early stages of life,
i.e. embryonic development, early growth after birth, and child-
hood (Burlingame 2009). Excess fat intake, however, is associated
with the rise in obesity. The consumption of particular types of fat
has been linked to a range of diseases and adverse health outcomes,
such as type 2 diabetes, coronary heart disease (CHD), stroke, and
certain types of cancer (FAO 2010).
Dietary fats are conventionally grouped into three broad groups
based on the number of double bonds the molecules exhibit, i.e.
(i) saturated fatty acids, (ii) monounsaturated fatty acids, and (iii)
polyunsaturated fatty acids. Saturated fats are acids with only sin-
gle bonds between adjacent carbon atoms, i.e. every carbon atom
carries its full quota of hydrogen atoms (Bender 2014). The most
notable dietary sources of saturated fats are animal products such as
meat, cow’s milk, eggs, butter, and salmon. Plant products, such as
palm oil, coconut, and chocolate/cocoa butter, are also substantial
sources of dietary saturated fat intake (Souza 2015). Unsaturated
fatty acids have one or more double bonds between carbon atoms:
monounsaturated fatty acids have only one of those double bonds
whereas polyunsaturated fatty acids have two or more. Monoun-
saturated fatty acids can be found in animal and vegetable prod-
ucts such as red meat, dairy products, and high-fat fruits. Many
polyunsaturated fatty acids can be found in most fats, whereas
certain nutritionally-important subtypes are mostly found in oily
fishes such as salmon or herring (FAO 2010).
Several authoritative dietary guidelines recommend that total fat
intake should contribute less than 30% of daily energy intake in
adults, and that saturated fats should be limited to less than 10%
of total energy intake (Eckel 2014; FAO 2010; FAO/WHO2015;
Lichtenstein 2006; NDA 2010; US Department of Agriculture
2010). Hence, when reducing the total fat intake, the share of
saturated fat should be lowered respectively. A recent systematic
review (Harika 2013), however, reported that in themajority of the
countries for which data were available (28 out of 45 countries),
average total fat intake was above the recommended 30% energy
threshold. The average proportion of energy contributed by total
fats ranged from 11.1% (in Bangladesh) to 46.2% (in Greece).
Moreover, for 29 countries the average saturated fat intake was
larger than the recommended 10% of total energy intake (ranging
from 2.9% (Bangladesh) to 20.9% (Indonesia) across all reported
countries). Only a few of the included studies reported data on the
distribution of fat intake within a population.Notably, the share of
the population with an intake above the recommended threshold
varied widely between countries (e.g. approximately 95% of the
Danish population has a saturated fat intake of more than 10%
energy, versus only 17% of the Indian population). In particular,
for LMICs the share of total fat and saturated fat intake is predicted
to increase as countries develop economically and socially and,
therefore, an increased intake will become a component of diets
across the globe (Popkin 2012; Wolmarans 2009).
Fat consumption and preventing obesity or
other adverse health outcomes
The role of dietary fat intake in the worldwide rise in obesity is
heavily debated. In particular two major issues stand out (Bray
1998): (i) can a decrease in overall fat intake lead to a decrease
of overweight and obesity, and (ii) can the increase of overweight
and obesity in LMICs be halted or slowed by preventing the pro-
gression towards a higher-fat diet. A recently published Cochrane
systematic review (commissioned by the WHO Nutrition Guid-
ance Expert Advisory Group (NUGAG) as part of the process of
updating the guidelines on fat intake) investigated the relationship
between total fat intake and obesity (Hooper 2015b). This review
excluded studies that recruited populations specifically for weight
loss and interventions intended to result in weight loss. Such stud-
ies are likely to be confounded by the implicit aim of reducing
calorie intake and, hence, may over-represent studies with obese
populations from Western countries. This would limit the trans-
ferability to non-obese populations or countries. Based on a meta-
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analysis of the included RCTs, the review authors concluded that
consuming a lower proportion of total energy from fat results in
small reductions in body weight (mean difference -1.54 kg, 95%
confidence interval (CI) -1.97 to -1.12 kg), waist circumference
(mean difference -0.30 cm, 95% CI -0.58 to -0.02 cm), and BMI
(mean difference -0.50, 95% CI -0.74 to -0.26) among adults.
Moreover, there was no suggestion of harms that might mitigate
any benefits of weight loss. The authors recommend that for popu-
lationswhere themean total fat intake is below30%of energy con-
sumed, such as in many LMICs, staying below this threshold may
help to avoid obesity. For populations where mean total fat intake
is above the 30% energy threshold, a reduction in intake below
this threshold may support the maintenance of healthy weights
(Hooper 2015b). The consumption of saturated fat has long been
suspected to increase the risk and incidence of CHD (Keys 1950).
However, the precise relationship is still being debated. A recent
Cochrane review investigated the relationship between saturated
fat intake and CVD (Hooper 2015a) and identified a robust ef-
fect on reducing combined cardiovascular events but not a general
effect on all-cause mortality or cardiovascular mortality. Regard-
ing the association between the intake of saturated fat and type
2 diabetes, a FAO expert group from their review of the litera-
ture concluded that there is a possible positive relationship (FAO
2010) but a recent review solely based on observational studies did
not identify such an association (Souza 2015). One recommended
alternative to reducing the total fat content of foods by lowering
the total amount of saturated fat in them, is replacing saturated
fat with polyunsaturated fat, as some of the latter fats may have a
beneficial health effect. Saturated fats are most commonly found
in processed or energy-dense, nutrient-poor food. The Cochrane
review suggests that replacing saturated fat with polyunsaturated
fat leads to a reduction in cardiovascular events (27% less), but this
is not the case for other types of replacement (e.g. protein or mo-
nounsaturated fats) (Hooper 2015a). Similarly, a recent Cochrane
review investigating the effect of increasing or decreasing amounts
of a certain type of polyunsaturated fat (Omega 6) did not find
evidence of any beneficial or harmful effects (Al-Khudairy 2015).
Therefore, reducing the share of total energy coming from fat will
have beneficial effects, while current evidence suggests that this
should be predominantly achieved through a reduction in the con-
tent of saturated fat.
Description of the intervention
Taxation as a fiscal measure is usually designed to raise revenue
for government expenditure. Taxation on commodities, however,
has also been used to influence consumer behavior, e.g. taxation
of foreign goods to discourage imports by making them more ex-
pensive, and to protect domestic producers. Similarly, taxation has
been used to generally disincentivise consumption (and produc-
tion). For example,many countries are considering or already have
introduced ’sin taxes’ on alcohol and tobacco to prevent alcohol
and tobacco use, often with the primary aim of preventing or re-
ducing resultant public health harms (Blecher 2015).
Current evidence on the health effects of the different types of di-
etary fats - as outlined above, and reflected in several dietary guide-
lines (Eckel 2014; FAO 2010; FAO/WHO 2015; Lichtenstein
2006;NDA2010;USDepartment of Agriculture 2010) - suggests
that a tax on fat content should be designed in such a way that
it may reduce the overall fat content by replacing unhealthy fats,
e.g. saturated fat. We will include all types of taxation targeting fat
contents in general but will pay special attention if and how less
desirable dietary fats, in particular saturated fats, are being affected
by the intervention.
Taxation to curb the content of fat in food is usually achieved
through indirect taxes, implemented either as a sales or an excise
tax (Sassi 2010). While producers or sellers pay the tax to the
government, they are usually expected to shift the tax burden to the
consumer by raising the price of the good in question. A sales tax
is usually added to the price of a product at the point of sale. Value
added tax (VAT; a special form of sales tax that is very common
in many European countries) avoids a taxation cascade when a
product has to go through a number of intermediaries by only
taxing the valued added by a producer/reseller, i.e. value added
equals sales price minus prices for input. The level of a sales tax
can differ by type of commodity. For example, the UK has three
different rates of VAT (standard: 20%, reduced: 5%, zero: no tax).
Introducing a (higher) tax on a targeted product, e.g. foods high
in saturated fat, may only require reassigning the product to a
different category (Mytton 2007). A disadvantage of sales taxes/
VAT, however, is that the tax is on the price and not on the volume
of the product (Bonnet 2013). As larger volumes of a product are
usually cheaper in relative terms than smaller volumes, the impact
of a sales tax could be reduced by increasing package size. Excise
taxes, on the other hand, are usually levied as a fixed rate per unit-
volume of content, independent of price or value.Hence, an excise
taxmay bemore able to reduce the incentives for consumers to buy
larger volumes of the taxed product, or switch to cheaper brands
with virtually identical fat content.
How the intervention might work
Standard economic theory predicts that a price increase leads to a
reduction in consumption. This finding, measured through elas-
ticities, has beenwell established, not least for health-relevant com-
modities such as tobacco and alcohol (Lhachimi 2012). However,
it is not always clear to what extent a tax will eventually increase re-
tail prices. Although indirect taxes are assumed to be shifted to the
consumer, examples exist where producers and retailers avoided
doing this fully, illustrated by calls for minimum unit pricing of
alcohol as a complement to taxation (Katikireddi 2014). In addi-
tion to increasing prices paid by the consumer as a consequence
of the tax, producers may broadly respond in two ways: first, tax-
ing (excessive saturated) fat content may lead to altered produc-
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tion processes resulting in lower saturated fat content in absolute
terms, by that also reducing total fat and the overall calorie con-
tent; and, second, producers may replace the share of saturated
fat with other fats or nutrients, or both. Hence, the new calorie
content may now be higher, lower, or unchanged. Moreover, these
new ingredients may or may not have further health implications
of their own. The first case is in line with the intention of such a
tax and is expected to have overall beneficial health outcomes. In
the second case, however, the effects of the changed food item on
obesity and overall health are unclear. Similarly, the consumer may
respond to tax-induced price increases with substitution, i.e. con-
suming a different product. Again, the effect of this substitution
on energy intake and health outcomes is uncertain (Miao 2013)
and the precise nature of the substitution may strongly depend
on cultural, geographical, and social factors. Price is only one de-
terminant among other environmental, social and cultural factors
that influence consumption behavior and individual diet (Dixon
2013). Lastly, themanner by which the intervention is introduced
and implemented may impact on its effectiveness. For example,
taxation introduced primarily for revenue-raising purposes may
not be set at a high enough level to influence behavior or may not
have an impact on awareness of the adverse health consequences
of the product.
A recent prominent example of a tax on saturated fat was a tax
implemented in Denmark in 2011 (and repealed at the end of
2012) (Vallgarda 2015). It was imposed only on certain food types
includingmeat, full-fat dairy products, animal fats, edible oils, and
margarine, and exempted food items with a saturated fat content
of 2.3% or less. The tax was an excise tax and the rate was set
at 16 Danish krone (approximate USD 2.90) per kilogram of
saturated fat contained in the food item (Jensen 2015). Several
publications investigated the effect of this tax. Jensen 2015 showed
that the tax had an insignificant or small negative effect on the
price of low- and medium-fat varieties of foods, but led to a 13%
to 16% price increase for high-fat varieties of minced beef and
cream products. Moreover, the tax induced substitution effects
in consumers. A second publication showed that the tax led to a
(modest) reduction in the share of energy from saturated fat, of
0.3% energy (Bødker 2015). Past potential examples of taxes on
saturated fat took place inMauritius andNorway which both used
reportedly “fiscal measures” to increase prices for food items high
in saturated fat (Dowse 1995; Norum 1997).
In Figure 1, we present a logic model showing the hypothesised
causal pathways between taxation of total fat/saturated fat and
obesity/other health outcomes. We anticipate that the introduc-
tion of a tax on saturated fat/total fat may influence prices or com-
position of food items, or both. The change in prices and/or com-
position of food items may affect buying behavior and, in turn,
food consumption. Through a change in composition and/or sub-
stitution, the new diet may result in lower, higher, or unaltered
energy intake. Similarly, the intake of total fat, saturated fat, and
other nutrients will be influenced. These expected changes may
have beneficial effects on obesity and/or other health outcomes.
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Figure 1. Logical model for taxation of saturated fat
Moreover, taxing a good depending on nutritional content sends
a strong signal from the government to consumers and producers
alike: the government is seriously concerned and is taking tangible
measures to curb consumption (Sassi 2016). For example, even if
the current level of taxation is low, once legislation for a tax is in
place, it becomes much easier to increase the tax level in the future
and the process of introducing a tax may raise awareness of the
adverse health effects and facilitate behavioral change.
Why it is important to do this review
The World Health Assembly and the WHO in their global strat-
egy on diet, physical activity and health stated that prices influence
consumption choices and that public policies can influence prices
through taxation, in ways that encourage healthy eating (Waxman
2004; WHO 2014). Moreover, taxes are considered highly cost-
effective public health actions as they may raise revenue that out-
strips implementation cost (Sassi 2014). This clearly demonstrates
the importance of tax interventions for public health.
The expected health effect of a tax on fat has been repeatedly
suggested and analysed in simulation studies for several countries
(Jørgensen 2013; Nnoaham 2009; Thiele 2010; Tiffin 2011). Pre-
vious systematic reviews investigated taxes on foods linked to obe-
sity in general and also included simulation studies (e.g. Eyles
2012; Maniadakis 2013; Thow 2014). However, a systematic re-
view of empirical evidence on the effect of taxing fat is lacking,
despite existing examples of taxes on fat or saturated fat.
This research will be part of a set of reviews of different types
of food taxes carried out by the same author group and sharing
the same methodological approach. Our reviews will focus on the
effects of governmental taxation on (i) fat content of processed or
packaged food (this review), (ii) sugar-sweetened beverages (Heise
2016), and (iii) unprocessed sugar or sugar-added foods (Pfinder
2016).
O B J E C T I V E S
To assess the effects of taxation of fat content in food on consump-
tion of total fat and saturated fat, energy intake, overweight, obe-
sity, and other adverse health outcomes in the general population.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We expect the relevant evidence to be comprised of heterogeneous
study designs. Beside small field studies, individual or cluster ran-
domisation are likely to be impossible for evaluations of taxation
interventions at a national level (Wansink 2014). Similarly, blind-
ing is all but impossible in the evaluation of national level inter-
ventions.
We will therefore consider evidence from various sources for this
review with respect to the quality of the study design, and adapt an
approach previously used in at least two other Cochrane reviews in
order to summarise ‘best available evidence’ (Gruen 2004; Turley
2013). This approach clearly separates studies into two broad cat-
egories: (1) studies meeting rigorous Cochrane Effective Practice
and Organisation of Care (EPOC) criteria, and (2) supporting
studies - those not meeting EPOC criteria, and having a higher
risk of bias.
First, for the synthesis of main results, in line with EPOC criteria
we will include:
• randomised controlled trials (RCTs);
• cluster randomised controlled trials (cRCTs);
• non-randomised controlled trials (nRCTs);
• controlled before-after (CBA) studies; and
• interrupted time series (ITS) studies.
According to EPOC, CBA studies require more than one inter-
vention or control site, and ITS studies require a clearly-defined
intervention time and at least three data points before and three
after the intervention (EPOC 2013).
There will be no restriction in terms of publication date, language
(CPH 2011), or study duration. Applications of taxes on saturated
fat or total fat at a national level might feature a longer time lag be-
tween intervention and outcomes, especially for health outcomes,
particularly as consumers might start stockpiling in expectation of
a tax being applied (Jensen 2015).
We will exclude simulation studies, due to their potential limi-
tations provoked by their basic assumptions (e.g. lack of poten-
tial supply-side changes, static models to predict weight loss), and
other methodological restrictions (e.g. the use of a combination
of heterogeneous data sources) (Lin 2011; Shemilt 2015).
Supporting studies
We will include as supporting studies:
• studies using an RCT, cRCT, nRCT, CBA, or ITS design
but not fulfilling the EPOC criteria;
• prospective cohort studies;
• retrospective/non-concurrent cohort studies;
• repeated cross-sectional studies; and
• uncontrolled before-after (UBA) studies.
Supporting studies will not be included in the statistical synthesis
of the primary included studies (i.e. those meeting EPOC criteria
(EPOC 2013)) but will be synthesised narratively in addition to
themain findings. We will extract the same type of data from these
supporting studies as we do for the included studies and will doc-
ument these in a separate ’Characteristics of supporting studies’
table. We will carry out ’Risk of bias’ assessments on these studies,
and undertake quality assessment, utilising theGRADE approach.
We will present the findings from these supporting studies sepa-
rately, as supplemental information in the results section and in
separate ’Summary of findings’ tables. Observations of similarities
and/or differences of findings from the included studies and the
supporting studies will be made in the ’Discussion’ section, to help
summarise the breadth, quality and the findings of the totality of
research on the effects of these interventions.
The supporting studies may support or challenge results in the
main findings and highlight uncertainty and potential research
gaps. We will consider known limitations of UBA, cohort, and
repeated cross-sectional studies for inclusion of studies, especially
confounding and/or time trends. If UBA, cohort, and repeated
cross-sectional studies are likely to be biased and do not use appro-
priate analytic strategies (e.g. stratification) or other designs (e.g.
regression discontinuity) to control for known confounders and/
or time trends, we will consider excluding these studies as ’sup-
porting studies’.
Types of participants
Wewill include studies irrespective of participants’ gender and age
(children: 0 to 17 years, and adults: 18 years and over) from any
country and setting.
We will exclude studies investigating the effects of taxing total fat
or saturated fat focusing on specific subgroups, particularly:
• people receiving pharmaceutical intervention;
• people undergoing a surgical intervention;
• pregnant females;
• professional athletes;
• ill people who are overweight or obese as a side-effect, such
as those with thyroiditis and depression; and
• people with chronic illness(es);
at baseline and at the post-intervention phase due to higher or
lower health risks compared to the general population.
Types of interventions
This review will include studies that evaluate the effects of taxes
on fat contents in foods. Such a tax can be expressed as sales, or
excise, or special VAT on the final product or an intermediary
product (Chriqui 2008; Chriqui 2013; Jou 2012; Mytton 2012).
Taxation maybe calculated either as a share of the food’s weight, or
as a share of the food’s energy. Current evidence on health effects
suggests that predominantly the content of saturated fats should
be reduced. Therefore it is anticipated that the tax is designed to
incentivise reductions in the amount of total or saturated fat in a
food item, or at least to incentivise replacement of saturated fat
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with other types of fat. The tax must be applied both for imports
and domestically-produced food items. We explicitly exclude im-
port taxes that only target selected food items that are high in
fat as this is usually not being done to curb consumption of fats
in general but to promote other, domestically-produced high fat
products (e.g. butter) (Meershoek 1984). We will include inter-
ventional studies of taxation at any taxation level, provided for
any duration, and studies that evaluate effects of artificial price
increases of high saturated fat food that mimic taxation in clearly-
defined environments (e.g. cafeterias, supermarkets, and vending
machines) (Epstein 2012). Interventions can be at the local, re-
gional, national, and multinational levels or field scenarios that
imitate taxation effects. We will include studies with any control
intervention, such as no intervention, as well as other food taxes,
bans, minimum pricing, media campaigns, or subsidies on healthy
foods (Jou 2012; Thow 2011).
Types of outcome measures
Our outcome selection and grouping was guided by preliminary
evidence as discussed in the Background, on the basis of the logic
model (Figure 1), and after feedback from the review advisory
board members (see Table 1). Detailed information on advisory
group involvement for this review is provided below. Primary out-
comes include intermediate non-health related outcomes directly
affected by tax-induced changes in food prices. As a result, con-
sumption and energy intake may directly alter the primary health
outcomes of overweight and obesity. Secondary outcomes will fo-
cus on food patterns (substitution and diet), expenditures, and
other health outcomes directly or indirectly influenced by taxation
of total fat/saturated fat content. We included demand as a proxy
for consumption (see How the intervention might work).
Primary outcomes
The reviewwill include changes frombaseline to post-intervention
in the following primary outcomes:
Consumption
• consumption of saturated fat (e.g. frequency, amount);
• consumption of total fat (e.g. frequency, amount);
Energy intake
• energy intake through saturated fat;
• energy intake through total fat;
• total energy intake;
Overweight and obesity
• incidence of overweight and obesity; and
• prevalence of overweight and obesity.
All primary outcomes can be measured by physicians and other
professionals or self-reported.Overweight and obesity can bemea-
sured by different anthropometric body mass indices, e.g. body
weight, BMI, skinfold thickness, waist circumference (WC),waist-
to-hip ratio (WHR), and waist-to-height ratio (WHtR), bio-
electrical impedance analysis (BIA), magnetic resonance imaging
(MRI), isotope dilution analysis (IDA), ultrasound and computed
tomography (CT) (WHO 2000). We will report changes in body
mass indices if no data are available on the incidence or prevalence
of overweight and obesity.
Secondary outcomes
The reviewwill include changes frombaseline to post-intervention
in the following secondary outcomes:
Substitution and diet
• composition of diet (expressed as food groups or
ingredients e.g. sugar, salt, fats);
Expenditures
• total expenditures on food;
• total expenditures on processed or packaged food
containing fat or saturated fat;
Demand
• total sales of processed or packaged food containing fat or
saturated fat;
Other health outcomes
• health-related quality of life (e.g. Short Form 36 (SF-36),
Health-Related Quality of Life (HRQOL-14));
• mortality; and
• any other health outcomes (e.g. type 2 diabetes,
cardiovascular diseases).
All secondary outcomes can be measured by physicians and other
professionals or self-reported.
Search methods for identification of studies
Electronic searches
We will search the following bibliographic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) viaCochrane Library (1948 to present);
• Cochrane Database of Systematic Reviews (CDSR) via
Cochrane Library (1995 to present);
• MEDLINE via OvidSP (1946 to present);
• Embase via OvidSP (1947 to present);
• PsycINFO via OvidSP (1887 to present);
• Current Contents Medicine Database of German and
German-language journals (CC MED) via LIVIVO (2000 to
present);
• LILACS via BIREME/VHL (1982 to present);
• EconLit via EBSCO (1969 to present);
• Campbell Library via Campbell Collaboration (2004 to
present);
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• Food Science and Technology Abstracts (FSTA) via OvidSP
(1969 to present);
• CINAHL via EBSCO (1937 to present); and
• Web of Science (SCI-EXPANDED, SSCI, A&HCI, CPCI-
S, CPCI-SSH, ESCI, CCR-EXPANDED, IC) via Thomson
Reuters (1900 to present).
We will apply a search strategy with additional keywords for pos-
sible comparators (e.g. “subsidy”) and we will not use filters for
study types, in order to maximise the sensitivity of the literature
search (Higgins 2011a, chapter 6.4.4). The search strategy for the
MEDLINE database is presented in Appendix 1. We will modify
this strategy to fit the syntax of the other databases. We will not
include African Index Medicus (AIM) - a valuable resource for
literature from low- and middle-income countries (LMICs) - in
our review as a sensitive preliminary search with intervention key
words (e.g. tax, taxation etc.) resulted in no hits.
Searching other resources
We will search the following electronic grey literature databases:
• ProQuest Dissertations & Theses Database (PQDT) via
ProQuest;
• System for Information on Grey Literature in Europe
(OpenGrey) via INIST/CNRS;
• Directory of Open Access Repositories (OpenDOAR) via
CRC;
• EconPapers via ORU;
• Social Science Research Network (SSRN eLibrary) via
SSRN; and
• National Bureau of Economic Research (NBER) via NBER.
We will search the following databases using keywords relevant to
the intervention (e.g. taxation, pricing), for completed or ongoing
studies:
• WHO’s International Clinical Trials Registry Platform
(WHO ICTRP) (which includes references of the
ClinicalTrials.gov database) (http://www.who.int/ictrp); and
• Trials Register of Promoting Health Interventions
(TRoPHI) (https://eppi.ioe.ac.uk).
Internet search engine
The first 30 hits in Google Scholar will be screened. We will use a
set of terms from our searches of the academic and grey literature
databases.
Targeted internet searching of key organisational
websites
Wewill search the websites ofmajor organisations and institutions,
specifically:
• World Obesity Federation (www.worldobesity.org);
• The Obesity Society (www.obesity.org);
• Organisation for Economic Co-operation and
Development (OECD) (www.oecd.org);
• World Health Organization (including regional web sites) (
www.who.int; filter: “all sites”);
• European Commission (ec.europa.eu/index˙en.htm);
• DG SANTE (ec.europa.eu/dgs/health˙food-safety/
index˙en.htm);
• Centers for Disease Control and Prevention (www.cdc.gov);
• National Institute for Health and Care Excellence (
www.nice.org.uk);
• World Trade Organization (www.wto.org); and
• World Cancer Research Fund Institute (www.wcrf.org/).
Searching other resources
The reference lists of all records of all included studies will be
searched by hand.
Advisory group
Wehave established a review advisory group (Higgins 2011a, chap-
ter 2.3.4.3) of experts in the field of food taxation and health
to comment and to give advice and suggestions based on the
manuscripts of the reviews on taxation of sugar-sweetened bev-
erages and unprocessed sugar. We provided the members of the
review advisory group with detailed background information on
those reviews. During the protocol stage, the group members were
asked to provide feedback specifically on the focus and the rele-
vance of this review’s question, selected endpoints, study design,
search strategy, database selection, and ongoing or unpublished
studies. The review advisory group consists of researchers, aca-
demics, and policy makers. We received feedback via email and
the online survey. All members of the advisory group are listed in
Table 1.
Data collection and analysis
Selection of studies
An information specialist will conduct the database searches. If a
reference or a full-text paper is not written in English, German,
or French, the relevant content will be translated to English by
using internet-based translators or we will ask for a translated ver-
sion by contacting native speakers (e.g. colleagues from co-operat-
ing research institutes) or the corresponding author of the article.
Screening will be conducted in six stages. First, titles of studies,
and abstracts if available, will be reviewed by at least two authors
independently. If an abstract is not provided by the database it
originates from, and the title appears to be potentially relevant,
we will progress the record to full-text review stage. Second, both
authors will compare their list of relevant studies and in case of any
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disagreement theywill seek the opinion of a third author to achieve
consensus. Third, full-text versions of potentially relevant studies
will be retrieved or obtained. Fourth, the full-text versions will
be screened by the two review authors independently. Fifth, each
author will create a list of the studies that are considered to fulfil
the inclusion criteria. Sixth, the two authors will compare their list
with each other and in case of any disagreement the opinion of a
third author will be decisive. Based on these six steps, studies will
be selected for inclusion in the review (Higgins 2011a, chapter
7). We will present a flow chart based on PRISMA to depict the
selection process (Moher 2009).
Data extraction and management
Data extraction will be performed independently by at least two
authors and both authors will compare the extracted data. Dis-
agreements will be resolved by a third author (Higgins 2011a,
chapter 7.6.2). We will use a modified data extraction and assess-
ment template fromCochrane PublicHealth (CPH) (CPH 2011).
Prior to the main data extraction process, the authors will pilot the
data extraction form to ensure standardised extraction. We will
extract general information (publication type, country of study,
funding source for study, potential conflict of interest), study eligi-
bility (type of study, participants, type of intervention, duration of
intervention, and type of outcome measures), study details (study
aim, methods, results, intervention group, confounders, and con-
founder-adjusted andunadjusted outcomes), indicators of changes
in food prices, and other relevant information (CPH 2011). Effect
estimates for study populations based on PROGRESS categories
(place of residence, race/ethnicity/culture/language, occupation,
gender/sex, religion, education, socioeconomic status (SES), so-
cial capital) will be extracted to evaluate impacts on equity. Other
contextual factors (political system, co-interventions, reason for
application, reason for certain tax level, intended beneficiaries, im-
plementation costs, country- and region-specific level of gross do-
mestic product (GDP), food security (availability, access, and use)
and process evaluation criteria (e.g. satisfaction of participants, ad-
herence)) that facilitate or hinder the application of the taxation
on saturated fat will be extracted as well (Anderson 2011). Data
will be entered into Review Manager 5 by one author. A second
author will double-check the data entered (RevMan 2014).
Assessment of risk of bias in included studies
The risk of bias of every included study will be evaluated inde-
pendently by at least two authors. In case of any disagreement,
discrepancies will be discussed with a third author and resolved by
consensus. Based on the template provided by CPH, the risk of
bias of RCTs, nRCTs, CBA and ITS studies will be assessed using
theCochrane Effective Practice andOrganisation of Care (EPOC)
Group’s guidance (CPH 2011), based on the Cochrane ’Risk of
bias’ tool. Both tools examine the following biases: selection, per-
formance, detection, attrition, reporting, and other (EPOC 2009;
Higgins 2011b). For interrupted time series (ITS) the EPOC ’Risk
of bias’ tool examines three further risks of bias: “Was the inter-
vention independent of other changes?”, “Was the shape of the
intervention effect pre-specified?”, and “Was the intervention un-
likely to affect data collection?” (EPOC 2009). The risk of bias of
supporting studies and non-randomised quantitative studies will
be assessed with the Quality Assessment Tool for Quantitative
Studies, developed by the Effective Public Health Practice Project
(EPHPP) (EPHPP 2010).
To judge the risk of bias according to Cochrane’s ’Risk of bias’
assessment tool and the EPOC guidance, we will use the following
categories: “low”, “high”, and “unclear” (e.g. information is lacking
or the risk of bias is unclear; Higgins 2011a, chapter 8.6). To
judge the risk of bias according to the Quality Assessment Tool for
Quantitative Studies, we will use the following three categories:
“strong”, “moderate”, and “weak” (EPHPP 2010).Wewill provide
’Risk of bias’ tables for all included studies.
Measures of treatment effect
We will report the effects of the treatment on dichotomous out-
comes as odds ratios (ORs), risk ratios (RRs) or risk differences
(RDs). In accordance with the recommendations from CPH, RRs
will be the preferred reported measure of treatment effect (CPH
2011). If RRs are not presented in the study, but data to calculate
the RRs are provided, we will calculate them. This also applies
for data suitable to calculate ORs (e.g. obesity prevalence). If data
to calculate the RRs are not provided, we will contact the corre-
sponding author of the study by email or phone to request the
RRs or the data to calculate them. If we cannot obtain RRs, we
will report the treatment effect from the study report.
We will express continuous data as mean differences (MDs) where
applicable or as standardised mean differences (SMDs). Shorter
ordinal data will be translated into dichotomous data (expressed as
ORs, RRs or RDs) and longer ordinal data will be treated as con-
tinuous data (expressed as MDs or SMDs). It is unclear whether
there is a cut-off point which is common across the studies and
can be used for dichotomisation (Higgins 2011a, chapter 7). The
cut-off point will be part of the sensitivity analysis. Count data
and Poisson data will be expressed as rate ratios. Time-to-event
data (survival data) will be translated into dichotomous data when
appropriate, or into hazard ratios (HRs).
If feasible, we will report the adjusted treatment effect. If a study
does not present adjusted treatment effect measures, we aim to
adjust the treatment effect measures for baseline variables by con-
ducting additional multivariate analyses as far as we have access to
the data or by contacting the corresponding author of the study
by email or phone to request the adjusted treatment effect mea-
sures. If studies present intention-to-treat effect estimates, thenwe
will prioritise these over average causal treatment effect estimates
(Higgins 2011a, chapter 9).
When the treatment effect is described in cost estimates as de-
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rived from economic studies, we will convert the cost estimates
to US dollars (USD) and the price year 2015 to compare cost
estimates from different studies with each other. To convert cost
estimates into USD, we will apply an international exchange rate
based on Purchasing Power Parities (PPPs). To convert cost esti-
mates to the year 2015, we will apply GDP deflators or implicit
price deflators for GDP. PPP conversion rates and GDP defla-
tor values will be derived from the International Monetary Fund
in the World Economic Outlook Database (http://www.imf.org/
external/data.htm) (Higgins 2011a, chapter 15).
Unit of analysis issues
We will collect data on studies irrespective of whether individu-
als or groups are allocated to an intervention or control group.
The analysis will consider the level at which allocation occurred,
e.g. cluster-RCTs, cross-over trials, and multiple observations (re-
peated observations on subjects, recurring events, multiple body
parts, and multiple intervention groups) for the same outcome
(Higgins 2011a, chapter 9.3.1). Limited by the quality of reported
data, we will consider data from cross-over trials (e.g. by incorpo-
rating the study data similar to a parallel group trial) and studies
with multiple observations (e.g. by defining different periods of
follow-up) (Higgins 2011a, chapter 9.3.4; chapter 16.4.5).
If control for clustering is missing or insufficient and if individual-
level data are not presented in the study, wewill request individual-
level data from the contact study author. If feasible, we will reduce
the size of each trial to its ’effective sample size’ in order to correct
intervention effects of cluster-RCTs.The effective sample size of an
intervention group is the original sample size divided by the ‘design
effect’. We will calculate the design effect by the formula 1 + (M
- 1) ICC. M is the average cluster size and ICC is the intracluster
correlation coefficient (Higgins 2011a, chapter 16.3.4).
For dichotomous data, both the total number of participants and
the number of participants who experience the event will be di-
vided by the same design effect. For continuous data, only the
sample size will be reduced; means and standard deviations will
remain unchanged (Higgins 2011a, chapter 16.3.4).
Dealing with missing data
We will request all missing information and data from principal
study authors by email or phone. The following steps will be taken
to deal with relevant missing data:
• contact the authors;
• screen the study and investigate important numerical data
such as randomised individuals as well as intention-to-treat
(ITT), as-treated and per-protocol (PP) populations;
• investigate attrition rates as part of the ’Risk of bias’
assessment in terms of dropouts, losses to follow-up and
withdrawals;
• critically appraise issues of missing data and imputation
methods (e.g. last observation carried forward (LOCF));
• impute missing standard deviations if contacted authors do
not respond (Higgins 2011a, chapter 16.1); and
• apply sensitivity analyses to estimate the impact of
imputation on meta-analyses.
Data ’notmissing at random’ due to systematic loss to follow-up or
systematic exclusion of individuals from studies will be requested
from study authors (Higgins 2011a, chapter 16.1.2).
Assessment of heterogeneity
In the event of substantial heterogeneity (methodological hetero-
geneity, statistical heterogeneity or considerable differences in the
type of study populations, interventions, comparisons, and out-
comes (PICO heterogeneity)), we will not perform meta-analysis.
Statistical heterogeneity will be detected through visual inspection
of the forest plots and by using a standard Chi² test with a signif-
icance level of P < 0.1. The I² statistic will be applied to quantify
inconsistency across studies and to assess the impact of hetero-
geneity on the meta-analysis. Potential reasons for heterogeneity
will be examined by conducting theoretically-informed subgroup
analyses (Higgins 2011a, chapter 9.5).
Methodological and PICO heterogeneity will be assessed through
tabulation and seeking explanations for heterogeneity between
study findings. We will consider potential sources of heterogeneity
such as:
• study population;
• geographical intervention area and intervention setting (e.g.
schools, workplace, supermarkets);
• intervention characteristics (tax definition, basis for
taxation, level of taxation);
• implementation level and duration;
• comparisons;
• co-interventions; and
• outcomes.
Assessment of reporting biases
Reporting biases, including publication bias, time lag bias, mul-
tiple (duplicate) publication bias, location bias, citation bias, lan-
guage bias, and outcome reporting bias, occur when the dissemina-
tion of research results depends on their magnitude and direction
(Higgins 2011a, chapter 10). If we find ten or more studies of the
same outcome, we will produce and assess funnel plots for study
effects resulting from reporting biases. When testing asymmetry
in funnel plots (small study effects), we will investigate whether
the relationship between a measure of study size and the estimated
intervention effect is asymmetrical (Higgins 2011a, chapter 10.4).
Funnel plots will be drawn using Review Manager 5 (RevMan
2014).
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Data synthesis
If two ormore studies report the same outcome and are sufficiently
homogenous conceptually, methodologically, and statistically, we
will performmeta-analyses of these studies using ReviewManager
5 (RevMan 2014). For dichotomous outcomes we will apply the
Mantel-Haenszel method and for continuous outcomes we will
apply the inverse variance method. For all analyses, the random-
effects method will be applied as we expect differences in the un-
derlying effect sizes due to contextual and application differences
(Higgins 2011a, chapter 9.5.4). If a study reports two or more
measures for the same outcome, then we will report the measure
that is most reported by the other included studies. If a study re-
ports multiple follow-ups for the same outcome (e.g. six months
during the intervention, one year during the intervention, and six
months after the intervention), we will prioritise the longest fol-
low-up during the intervention (e.g. one year during the interven-
tion in the example given). Nevertheless, we will extract all follow-
up data.
First, we will structure narrative synthesis by outcome categories
of this review. Second, within these categories wewill make further
separation according to intervention setting (i.e. field scenarios,
evaluation of implemented fat taxes) and study design (e.g. RCT,
cRCT, nRCT, CBA, and ITS etc.) or study quality (Ryan 2016).
Study results with insufficient homogeneity will be synthesised
narratively. In addition to reporting findings as text and tables,
we may consider both harvest plots and effect direction plots to
summarise data not suitable for meta-analyses. Harvest plots are
graphical summaries of data (represented by multiple shaded or
non-shaded bars with varying heights) and can be used to indicate
effect directions across included studies with non-standardised ef-
fect estimates of outcomes (e.g. anthropometric measures). Sim-
ilarly, effect direction plots can be used to visualise information
on effect directions with more focus on direct comparisons across
studies (Ogilvie 2008; Thomson 2013).
We will provide a ‘Summary of findings’ table containing the out-
comes of greatest interest for decision makers. Therefore, we will
include at least the following outcomes: consumption of total fat,
consumption of saturated fat, total energy intake, composition of
diet prevalence of overweight or obesity, and total sales. This pre-
selected list is based on feedback from our advisory group and
external reviewers. This table will include information on the out-
comes, comparative risks, the relative effect, the number of par-
ticipants, the number of studies included, the quality of evidence
based on GRADE, and additional comments. If feasible, we will
use the GRADEprofiler software to prepare the ‘Summary of find-
ings’ table (GRADE 2013; GRADEpro; Higgins 2011a, chapter
11).
Results of data synthesis will also be mapped against our initial
logic model, to refine the theory of change and to assess the cred-
ibility of the assumed causal pathways.
Subgroup analysis and investigation of heterogeneity
Wewill investigate the following subgroups for primary outcomes,
where feasible:
• high-income countries versus middle- and low-income
countries;
• high-income groups versus middle- and low-income groups;
• high-educated groups versus low-educated groups;
• different levels of taxation;
• single tax versus multiple taxes on fat content;
• tax on saturated fat alone versus tax on saturated fat
accompanied by other fat taxes;
• tax on fat accompanied by other interventions (e.g. bans,
minimum pricing, media campaigns, or subsidies of healthy
foods);
• different types of taxation (e.g. excise tax or VAT);
• children versus adults;
• BMI subgroups.
If data are available, we will perform subgroup analyses according
to dimensions of disadvantage based on PROGRESS categories
(e.g. place of residence, gender, education) (Anderson 2011). If
feasible, we will investigate the statistical significance of differences
in the treatment effect between subgroups using t-tests and Chi²
tests.
Sensitivity analysis
Sensitivity analyses will be performed to determine the robustness
of our results by conducting separate meta-analyses and presenting
harvest plots for the studies included in our review according to
the following factors:
• studies at ‘low risk of bias’ compared to those at ‘high risk
of bias’;
• source of funding;
• published studies versus unpublished studies;
• intervention duration;
• follow-up time;
• objective measures compared to subjective measures;
• study design;
• cut-off points of the measures of the treatment effect; and
• imputation of data.
Studies assessed with a high or unclear risk of bias with respect
to incomplete outcome data and baseline differences will not be
included in these analyses. For cRCTswith adequate data provided,
we will perform intracluster correlation value sensitivity analysis.
We will report findings of sensitivity analyses as a summary table
(Higgins 2011a, chapter 9.7).
A C K N OW L E D G E M E N T S
11Taxation of the fat content of foods for reducing their consumption and preventing obesity or other adverse health outcomes (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We thank the members of the review advisory group for their
valuable comments and suggestions to improve our manuscript:
Cristina Cleghorn (Department of Public Health, University of
Otago, Wellington, NZ), Emilia Crighton (Faculty of Public
Health, London, UK), Peter Faassen de Heer (CMO and Pub-
lic Health Directorate Scottish Government, Edinburgh, UK),
Dionne Mackison (Department for International Development,
UK Government, Glasgow, UK), Barry Popkin (Professor of
Global Nutrition, University of North Carolina, Chapel Hill,
USA), and Torben Jørgensen (Professor Department of Public
Health University of Copenhagen, Copenhagen, DK). We are
thankful to Jodie Doyle, Miranda Cumpstone and Rob Ander-
son (Cochrane Public Health) for editorial guidance and Daniela
Küllenberg de Gaudry, Mary-Anne Land, and Beth Thomas for
their valuable comments as external referees. We thank Tatjana
Paeck, Caroline Henning, and Sarina Schwarz for their ardent re-
search support. Moreover, we acknowledge the contribution of
Kylie Thaler for hermethodological input to improve the protocol
draft.
R E F E R E N C E S
Additional references
Al-Khudairy 2015
Al-Khudairy L, Hartley L, Clar C, Flowers N, Hooper
L, Rees K. Omega 6 fatty acids for the primary
prevention of cardiovascular disease. Cochrane Database
of Systematic Reviews 2015, Issue 11. [DOI: 10.1002/
14651858.CD011094.pub2]
Anderson 2011
Anderson LM, Petticrew M, Rehfuess E, Armstrong R,
Ueffing E, Baker P. Equity checklist for systematic review
authors. equity.cochrane.org/sites/equity.cochrane.org/files/
uploads/equitychecklist2011.pdf (accessed 21 April 2015).
Bender 2014
Bender DA. A dictionary of food and nutrition.
www.oxfordreference.com/view/10.1093/acref/
9780199234875.001.0001/acref-9780199234875
(accessed 01 February 2016).
Blecher 2015
Blecher E. Taxes on tobacco, alcohol and sugar sweetened
beverages: Linkages and lessons learned. Social Science &
Medicine 2015;136-7:175–9.
Bonnet 2013
Bonnet C. How to set up an effective food tax? Comment
on “Food Taxes: A New Holy Grail?”. International Journal
of Health Policy and Management 2013;1(3):233–4.
Bray 1998
Bray GA, Popkin BM. Dietary fat intake does affect obesity!.
American Journal of Clinical Nutrition 1998;68(6):1157–73.
Burlingame 2009
Burlingame B, Nishida C, Uauy R, Weisell R. Fats and fatty
acids in human nutrition: introduction. Annals of Nutrition
& Metabolism 2009;55(1-3):5–7.
Bødker 2015
Bødker M, Pisinger C, Toft U, Jørgensen T. The Danish fat
tax-effects on consumption patterns and risk of ischaemic
heart disease. Preventive Medicine 2015;77:200–3.
Chriqui 2008
Chriqui JF, Eidson SS, Bates H, Kowalczyk S, Chaloupka
FJ. State sales tax rates for soft drinks and snacks sold
through grocery stores and vending machines, 2007.
Journal of Public Health Policy 2008;29(2):226–49. [DOI:
10.1057/jphp.2008.9]
Chriqui 2013
Chriqui JF, Chaloupka FJ, Powell LM, Eidson SS. A
typology of beverage taxation: multiple approaches for
obesity prevention and obesity prevention-related revenue
generation. Journal of Public Health Policy 2013;34(3):
403–23. [DOI: 10.1057/jphp.2013.17]
CPH 2011
Cochrane Public Health. Guide for develop-
ing a Cochrane protocol. ph.cochrane.org/
sites/ph.cochrane.org/files/uploads/
Guide%20for%20PH%20protocol˙Nov%202011˙final%20for%20website.pdf
(accessed 25 June 2015).
Dixon 2013
Dixon J, Isaacs B. Why sustainable and ’nutritionally
correct’ food is not on the agenda: Western Sydney, the
moral arts of everyday life and public policy. Food Policy
2013;43:67–76. [DOI: 10.1016/j.foodpol.2013.08.010]
Dowse 1995
Dowse GK, Gareeboo H, Alberti KG, Zimmet P,
Tuomilehto J, Purran A, et al. Changes in population
cholesterol concentrations and other cardiovascular risk
factor levels after five years of the non-communicable disease
intervention programme in Mauritius. Mauritius Non-
communicable Disease Study Group. BMJ (Clinical research
ed.) 1995;311(7015):1255–9.
Eckel 2014
Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller
N, Hubbard VS, et al. 2013 AHA/ACC guideline on
lifestyle management to reduce cardiovascular risk: a report
of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines. Journal of
the American College of Cardiology 2014;63(25):3027–8.
EPHPP 2010
Effective Public Health Practice Project (EPHPP). Quality
assessment tool for quantitative studies. www.ephpp.ca/
PDF/Quality%20Assessment%20Tool˙2010˙2.pdf
(accessed 29 July 2015).
12Taxation of the fat content of foods for reducing their consumption and preventing obesity or other adverse health outcomes (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
EPOC 2009
The Effective Practice and Organisation of Care group
(EPOC). Suggested risk of bias criteria for EPOC reviews.
epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/
Suggested risk of bias criteria for EPOC reviews.pdf
(accessed 25 July 2015).
EPOC 2013
The Effective Practice and Organisation of Care group
(EPOC). What study designs should be included in an
EPOC review?. epoc.cochrane.org/sites/epoc.cochrane.org/
files/uploads/05 What study designs should be included in
an EPOC review 2013 08 12˙2.pdf (accessed 1 December
2015).
Epstein 2012
Epstein LH, Jankowiak N, Nederkoorn C, Raynor
HA, French SA, Finkelstein E. Experimental research
on the relation between food price changes and food-
purchasing patterns: a targeted review. American Journal of
Clinical Nutrition 2012;95(4):789–809. [DOI: 10.3945/
ajcn.111.024380]
Eyles 2012
Eyles H, Ni Mhurchu C, Nghiem N, Blakely T. Food
pricing strategies, population diets, and non-communicable
disease: a systematic review of simulation studies. PLoS
Medicine 2012;9(12):e1001353.
FAO 2010
FAO. Fats and fatty acids in human nutrition. FAO Food
and Nutrition Paper. Vol. 91, Rome: Food and Agriculture
Organization of the United Nations, 2010.
FAO/WHO 2015
Food, Agriculture Organization of the United Nations.
World Health Organization. Second International
Conference on Nutrition (ICN2). Report of the Joint FAO/
WHO Secretariat on the Conference. Rome, 2015.
Goryakin 2015
Goryakin Y, Lobstein T, James WPT, Suhrcke M. The
impact of economic, political and social globalization on
overweight and obesity in the 56 low and middle income
countries. Social Science & Medicine 2015;133:67–76.
GRADE 2013
The GRADE Working Group. Handbook for grading the
quality of evidence and the strength of recommendations
using the GRADE approach. Updated October 2013.
www.guidelinedevelopment.org/handbook/ (accessed 26
May 2015).
GRADEpro [Computer program]
GRADE Working Group, McMaster University.
GRADEpro GDT. Version accessed 18 October 2016.
Hamilton (ON): GRADE Working Group, McMaster
University, 2014.
Gruen 2004
Gruen RL, Weeramanthri TS, Knight SE, Bailie RS.
Specialist outreach clinics in primary care and rural hospital
settings. Cochrane Database of Systematic Reviews 2004,
Issue 1. [DOI: 10.1002/14651858.CD003798.pub2]
Guh 2009
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham
CL, Anis AH. The incidence of co-morbidities related to
obesity and overweight: a systematic review and meta-
analysis. BMC Public Health 2009;9(1):1–20. [DOI:
10.1186/1471-2458-9-88]
Harika 2013
Harika RK, Eilander A, Alssema M, Osendarp SJM, Zock
PL. Intake of fatty acids in general populations worldwide
does not meet dietary recommendations to prevent coronary
heart disease: a systematic review of data from 40 countries.
Annals of Nutrition & Metabolism 2013;63(3):229–38.
Heise 2016
Heise TL, Katikireddi SV, Pega F, Gartlehner G, Fenton C,
Griebler U, et al. Taxation of sugar-sweetened beverages
for reducing their consumption and preventing obesity
or other adverse health outcomes. Cochrane Database
of Systematic Reviews 2016, Issue 8. [DOI: 10.1002/
14651858.CD012319]
Higgins 2011a
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
[updated March 2011]. The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
Higgins 2011b
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D,
Oxman AD, et al. The Cochrane Collaboration’s tool for
assessing risk of bias in randomised trials. BMJ 2011;343:
d5928. [DOI: 10.1136/bmj.d5928]
Hooper 2015a
Hooper L, Martin N, Abdelhamid A, Davey SG. Reduction
in saturated fat intake for cardiovascular disease. Cochrane
Database of Systematic Reviews 2015, Issue 6. [DOI:
10.1002/14651858.CD011737]
Hooper 2015b
Hooper L, Abdelhamid A, Bunn D, Brown T, Summerbell
CD, Skeaff CM. Effects of total fat intake on body weight.
Cochrane Database of Systematic Reviews 2015, Issue 8.
[DOI: 10.1002/14651858.CD011834]
Jensen 2015
Jensen JD, Smed S, Aarup L, Nielsen E. Effects of the
Danish saturated fat tax on the demand for meat and dairy
products. Public Health Nutrition 2015 Aug 26 [Epub
ahead of print].
Jou 2012
Jou J, Techakehakij W. International application of sugar-
sweetened beverage (SSB) taxation in obesity reduction:
factors that may influence policy effectiveness in country-
specific contexts. Health Policy 2012;107(1):83–90. [DOI:
10.1016/j.healthpol.2012.05.011]
Jørgensen 2013
Jørgensen T, Capewell S, Prescott E, Allender S, Sans S,
Zdrojewski T, et al. Population-level changes to promote
cardiovascular health. European Journal of Preventive
Cardiology 2013;20(3):409–21.
13Taxation of the fat content of foods for reducing their consumption and preventing obesity or other adverse health outcomes (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Katikireddi 2014
Katikireddi SV, Hilton S, Bonell C, Bond L. Understanding
the development of minimum unit pricing of alcohol in
Scotland: a qualitative study of the policy process. PLoS
ONE 2014;9:e91185.
Keys 1950
Keys A, Mickelsen O, Miller E von O, Chapman CB. The
relation in man between cholesterol levels in the diet and in
the blood. Science 1950;112(2899):79–81.
Lang 2009
Lang T, Barling D, Caraher M. Food Policy. Oxford (UK):
Oxford University Press, 2009.
Lhachimi 2012
Lhachimi SK, Cole KJ, Nusselder WJ, Smit HA, Baili P,
Bennett K, et al. Health impacts of increasing alcohol prices
in the European Union: a dynamic projection. Preventive
Medicine 2012;55(3):237–43.
Lhachimi 2013
Lhachimi SK, Nusselder WJ, Lobstein TJ, Smit HA, Baili
P, Bennett K, et al. Modelling obesity outcomes: reducing
obesity risk in adulthood may have greater impact than
reducing obesity prevalence in childhood. Obesity Reviews
2013;14(7):523–31. [PUBMED: 23601528]
Lhachimi 2016
Lhachimi SK, Nusselder WJ, Smit HA, Baili P, Bennett
K, Fernández E, et al. Potential health gains and health
losses in eleven EU countries attainable through feasible
prevalences of the life-style related risk factors alcohol, BMI,
and smoking: a quantitative health impact assessment.
BMC Public Health 2016;16(1):734. [DOI: 10.1186/
s12889-016-3299-z]
Lichtenstein 2006
Lichtenstein AH, Appel LJ, Brands M, Carnethon
M, Daniels S, Franch HA, et al. Diet and lifestyle
recommendations revision 2006: a scientific statement from
the American Heart Association Nutrition Committee.
Circulation 2006;114:82–96.
Lin 2011
Lin BH, Smith TA, Lee JY, Hall KD. Measuring weight
outcomes for obesity intervention strategies: the case of a
sugar-sweetened beverage tax. Economics and Human Biology
2011;9(4):329–41. [DOI: 10.1016/j.ehb.2011.08.007]
Maniadakis 2013
Maniadakis N, Kapaki V, Damianidi L, Kourlaba G.
A systematic review of the effectiveness of taxes on
nonalcoholic beverages and high-in-fat foods as a means
to prevent obesity trends. ClinicoEconomics and Outcomes
Research 2013;5:519–43.
Meershoek 1984
Meershoek CJM. The E.C. tax threat. Journal of the
American Oil Chemists’ Society 1984;61(4):722–3.
Miao 2013
Miao Z, Beghin JC, Jensen HH. Accounting for product
substitution in the analysis of food taxes targeting obesity.
Health Economics 2013;22(11):1318–43.
Moher 2009
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA
Group. Preferred Reporting Items for Systematic
Reviews and Meta-Analyses: the PRISMA statement.
PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/
journal.pmed.1000097]
Mytton 2007
Mytton O, Gray A, Rayner M, Rutter H. Could targeted
food taxes improve health?. Journal of Epidemiology and
Community Health 2007;61(8):689–94.
Mytton 2012
Mytton OT, Clarke D, Rayner M. Taxing unhealthy food
and drinks to improve health. BMJ 2012;344:e2931.
[DOI: 10.1136/bmj.e2931]
NCD-RisC 2016
NCD Risk Factor Collaboration (NCD-RisC). Trends in
adult body-mass index in 200 countries from 1975 to 2014:
a pooled analysis of 1698 population-based measurement
studies with 19.2 million participants. Lancet 2016;387
(10026):1377–96. [DOI: http://dx.doi.org/10.1016/
S0140-6736(16)30054-X]
NDA 2010
EFSA Panel on Dietetic Products, Nutrition, Allergies
(NDA). Scientific opinion on dietary reference values for
fats, including saturated fatty acids, polyunsaturated fatty
acids, monounsaturated fatty acids, trans fatty acids, and
cholesterol. EFSA Journal 2010;8(3):1461.
Ng 2014
Ng M, Fleming T, Robinson M, Thomson B, Graetz N,
Margono C, et al. Global, regional, and national prevalence
of overweight and obesity in children and adults during
1980-2013: a systematic analysis for the Global Burden of
Disease Study 2013. Lancet 2014;384(9945):766–81.
Nnoaham 2009
Nnoaham KE, Sacks G, Rayner M, Mytton O, Gray A.
Modelling income group differences in the health and
economic impacts of targeted food taxes and subsidies.
International Journal of Epidemiology 2009;38(5):1324–33.
Norum 1997
Norum KR, Johansson L, Botten G, Bjørneboe GE,
Oshaug A. Nutrition and food policy in Norway: effects
on reduction of coronary heart disease. Nutrition Reviews
1997;55(11 Pt 2):S32–9.
Ogilvie 2008
Ogilvie D, Fayter D, Petticrew M, Sowden A, Thomas
S, Whitehead M, et al. The harvest plot: a method for
synthesising evidence about the differential effects of
interventions. BMC Medical Research Methodology 2008;8
(1):8. [DOI: 10.1186/1471-2288-8-8]
Pfinder 2016
Pfinder M, Katikireddi SV, Pega F, Gartlehner G, Fenton
C, Griebler U, et al. Taxation of unprocessed sugar or
sugar-added foods for reducing their consumption and
preventing obesity or other adverse health outcomes.
14Taxation of the fat content of foods for reducing their consumption and preventing obesity or other adverse health outcomes (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cochrane Database of Systematic Reviews 2016, Issue 8.
[DOI: 10.1002/14651858.CD012333]
Popkin 2012
Popkin M, Adair LS, Ng SW. Global nutrition transition
and the pandemic of obesity in developing countries.
Nutrition Reviews 2012;70(1):3–21.
RevMan 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Ryan 2016
Ryan R, Cochrane Consumers and Communication
Review Group. Cochrane Consumers and Communication
Review Group: data synthesis and analysis.
cccrg.cochrane.org/sites/cccrg.cochrane.org/files/uploads/
AnalysisRestyled˙FINAL%20June%2020%202016.pdf
(accessed 22 July 2016).
Sassi 2010
Sassi F, Organisation for Economic Co-operation and
Development. Obesity and the Economics of Prevention. Fit
not Fat. Paris: OECD Publishing, 2010.
Sassi 2014
Sassi F, Belloni A. Fiscal incentives, behavior change and
health promotion: what place in the health-in-all-policies
toolkit?. Health Promotion International 2014;29 Suppl 1:
i103–12.
Sassi 2016
Sassi F. Taxing sugar. BMJ (Clinical research ed.) 2016;352:
h6904.
Seidell 2015
Seidell JC, Halberstadt J. The global burden of obesity
and the challenges of prevention. Annals of Nutrition &
Metabolism 2015;66 Suppl 2:7–12.
Shemilt 2015
Shemilt I, Marteau TM, Smith RD, Ogilvie D. Use and
cumulation of evidence from modelling studies to inform
policy on food taxes and subsidies: biting off more than
we can chew?. BMC Public Health 2015;15:297. [DOI:
10.1186/s12889-015-1641-5]
Souza 2015
Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe
T, et al. Intake of saturated and trans unsaturated fatty acids
and risk of all cause mortality, cardiovascular disease, and
type 2 diabetes: systematic review and meta-analysis of
observational studies. BMJ (Clinical research ed.) 2015;351:
h3978.
Thiele 2010
Thiele S. Fat tax: a political measure to reduce overweight?
The case of Germany. The Economics of Food,
Food Choice and Health. 1st Joint EAAE/AAEA
Seminar. ageconsearch.umn.edu/bitstream/116393/2/1C-
1˙%20Thiele.pdf (accessed 1 February 2016).
Thomson 2013
Thomson HJ, Thomas S. The effect direction plot: visual
display of non-standardised effects across multiple outcome
domains. Research Synthesis Methods 2013;4(1):95–101.
[DOI: 10.1002/jrsm.1060]
Thow 2011
Thow AM, Quested C, Juventin L, Kun R, Khan
AN, Swinburn B. Taxing soft drinks in the Pacific:
implementation lessons for improving health. Health
Promotion International 2011;26(1):55–64. [DOI:
10.1093/heapro/daq057]
Thow 2014
Thow AM, Downs S, Jan S. A systematic review of the
effectiveness of food taxes and subsidies to improve diets:
understanding the recent evidence. Nutrition Reviews 2014;
72(9):551–65.
Tiffin 2011
Tiffin R, Arnoult M. The public health impacts of a fat tax.
European Journal of Clinical Nutrition 2011;65(4):427–33.
Turley 2013
Turley R, Saith R, Bhan N, Rehfuess E, Carter B. Slum
upgrading strategies involving physical environment
and infrastructure interventions and their effects on
health and socio-economic outcomes. Cochrane Database
of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/
14651858.CD010067.pub2]
US Department of Agriculture 2010
US Department of Agriculture and US Department
of Health and Human Services. Dietary Guidelines for
Americans. 7th Edition. Washington, DC: US Government
Printing office, 2010.
Vallgarda 2015
Vallgarda S, Holm L, Jensen JD. The Danish tax on
saturated fat: why it did not survive. European Journal of
Clinical Nutrition 2015;69(2):223–6.
Wansink 2014
Wansink B, Hanks AS, Cawley J, Just DR. From coke
to coors: a field study of a fat tax and its unintended
consequences (2014). ssrn.com/abstract=2473623. Cornell
University: Cornell University, (accessed 30 June 2015).
Waxman 2004
Waxman A. WHO global strategy on diet, physical activity
and health. Food and Nutrition Bulletin 2004;25(3):
292–302.
WHO 2000
WHO. Obesity: preventing and managing the global
epidemic. Report of a WHO consultation. World Health
Organization Technical Report Series 2000; Vol. 894.
WHO 2011
WHO. International Statistical Classification of Diseases
and Related Health Problems. Geneva: World Health
Organization, 2011.
15Taxation of the fat content of foods for reducing their consumption and preventing obesity or other adverse health outcomes (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
WHO 2014
WHO. Global status report on noncommunicable diseases
2014. Global Status Report on Noncommunicable Diseases
2014. Geneva: World Health Organization, 2014.
Wolmarans 2009
Wolmarans P. Background paper on global trends in food
production, intake and composition. Annals of Nutrition &
Metabolism 2009;55(1-3):244–72.
∗ Indicates the major publication for the study
A D D I T I O N A L T A B L E S
Table 1. Advisory group members
Name Occupation
Cristina Cleghorn Department of Public Health, University of Otago, Wellington, NZ
Emilia Crighton Faculty of Public Health, London, UK
Peter Faassen de Heer CMO and Public Health Directorate Scottish Government, Edinburgh, UK
Dionne Mackison Department for International Development, UK Government, Glasgow, UK
Barry Popkin Professor of Global Nutrition, University of North Carolina, Chapel Hill, US
Torben Jørgensen Professor Department of Public Health University of Copenhagen, Copenhagen, DK
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp Taxes/
2. exp Government Programs/ec, lj [Economics, Legislation & Jurisprudence]
3. exp Health Policy/ec, lj [Economics, Legislation & Jurisprudence]
4. exp Food Dispensers, Automatic/ec, lj, sn [Economics, Legislation & Jurisprudence, Statistics & Numerical Data]
5. exp Health Promotion/ec, lj [Economics, Legislation & Jurisprudence]
6. exp Nutrition Policy/ec, lj [Economics, Legislation & Jurisprudence]
7. exp Public Health/ec, lj [Economics, Legislation & Jurisprudence]
8. “demand elasticity”.tw.
9. “policy intervention*”.tw.
10. “sales tax”.tw.
11. “thin subsidies”.tw.
12. “vending machine*”.tw.
13. budget.tw.
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14. excise.tw.
15. fiscal.tw.
16. levied.tw.
17. levy.tw.
18. price.tw.
19. priced.tw.
20. prices.tw.
21. pricing.tw.
22. subsidy.tw.
23. subsidies.tw.
24. tax.tw.
25. taxation.tw.
26. taxed.tw.
27. taxes.tw.
28. taxing.tw.
29. OR/1-28
30. exp Dietary Carbohydrates/
31. exp Dietary Sucrose/
32. exp High Fructose Corn Syrup/
33. “chewing gum”.tw.
34. “dietary sucrose”.tw.
35. ((“energy dens*” or “highenergy” or “high energy” or “high-energy” or “low energy” or chips) and (fat* or sugar* or sweet* or food
or diet* or nutrition or overweight or drink* or beverage* or protein* or carbohydrate*)).tw.
36. “HED calori*”.tw.
37. “HED-calori*”.tw.
38. “highcalori* food*”.tw.
39. “high calori* food*”.tw.
40. “high-calori* food*”.tw.
41. “lowcalori* food*”.tw.
42. “low calori* food*”.tw.
43. “low-calori* food*”.tw.
44. “ice cream*”.tw.
45. “unhealthy food*”.tw.
46. bakery.tw.
47. biscuit*.tw.
48. cacao.tw.
49. cake*.tw.
50. calorie*.tw.
51. candy.tw.
52. candies.tw.
53. bonbon*.tw.
54. chocolate*.tw.
55. confectionar*.tw.
56. cookie*.tw.
57. isoglucose.tw.
58. jam.tw.
59. jelly.tw.
60. jellies.tw.
61. liquorice.tw.
62. macronutrient*.tw.
63. maltose.tw.
64. marmalade.tw.
65. marzipan.tw.
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66. pastr*.tw.
67. sucrose.tw.
68. sugar.tw.
69. sugars.tw.
70. sugary.tw.
71. sweet*.tw.
72. exp Butter/
73. exp Dietary Fats/
74. exp Energy Intake/
75. exp Fast Foods/
76. exp Margarine/
77. exp Plant Oils/ec [Economics]
78. “fastfood*”.tw.
79. “fast food*”.tw.
80. “fast-food*”.tw.
81. “fattening-food*”.tw.
82. “fattening food*”.tw.
83. “fried food*”.tw.
84. (coconut OR cooking OR palmOR vegetable OR soya OR soybean OR rapeseedOR linseed OR sunflower OR sesame OR peanut
OR groundnut OR copra OR babassu OR olive OR thistle ADJ Oil).tw.
85. “salty-snack*”.tw.
86. “salty snack*”.tw.
87. “snack food*”.tw.
88. “snack-food*”.tw.
89. “takeaway food*”.tw.
90. “takeaway-food*”.tw.
91. “take away food*”.tw.
92. “take away-food*”.tw.
93. “take-away food*”.tw.
94. “take-away-food*”.tw.
95. “whole milk”.tw.
96. burger*.tw.
97. butter.tw.
98. cheese.tw.
99. cream.tw.
100. crisps.tw.
101. (egg AND (fat* or sugar* or sweet* or food or diet* or nutrition or overweight or drink* or beverage* or protein* or carbohy-
drate*)).tw.
102. (eggs AND (fat* or sugar* or sweet* or food or diet* or nutrition or overweight or drink* or beverage* or protein* or carbohy-
drate*)).tw.
103. (fat AND (Food* or diet* or nutrition or nutrient or eat* or meal* or oil* or carbohydrate* or protein* or obesity or obese)).tw.
104. (fatty AND (Food* or diet* or nutrition or nutrient or eat* or meal* or oil* or carbohydrate* or protein* or obesity or obese)).tw.
105. fats.tw.
106. fattening.tw.
107. fries.tw.
108. ghee.tw.
109. lard.tw.
110. margarine.tw.
111. mono-unsat*.tw.
112. monounsat*.tw.
113. omega3.tw.
114. “omega 3”.tw.
115. omega-3.tw.
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116. pizza.tw.
117. polyunsat*.tw.
118. poly-unsat*.tw.
119. sausage*.tw.
120. suet.tw.
121. exp Carbonated Beverages/
122. exp Food Preferences/
123. exp Food Habits/
124. “caloric-drink*”.tw.
125. “caloric drink*”.tw.
126. “carbonated-beverage*”.tw.
127. “carbonated beverage*”.tw.
128. “carbonated-drink*”.tw.
129. “carbonated drink*”.tw.
130. “energy-drink*”.tw.
131. “energy drink*”.tw.
132. “fizzy-drink*”.tw.
133. “fizzy drink*”.tw.
134. “high-calori* drink*”.tw.
135. “high calori* drink*”.tw.
136. “soda pop”.tw.
137. “soft-drink*”.tw.
138. “soft drink*”.tw.
139. “sport-drink*”.tw.
140. “sport* drink*”.tw.
141. “sport*-drink*”.tw.
142. cola.tw.
143. soda.tw.
144. SSB*.tw.
145. syrup*.tw.
146. OR/30-145
147. 29 AND 146
148. (animals NOT (humans AND animals)).sh.
149. 147 NOT 148
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